1. |
Eyler CE, Rich JN. Survival of the fittest: cancer stem cells in therapeutic resistance and angiogenesis. J Clin Oncol, 2008, 26(17): 2839-2845.
|
2. |
Liu Y, Gu X, Lin Q, et al. Prognostic significance of osteopontin in patients with non-small cell lung cancer: results from a meta-analysis. Int J Clin Exp Med, 2015, 8(8): 12765-12773.
|
3. |
Bramwell VH, Tuck AB, Chapman JA, et al. Assessment of osteopontin in early breast cancer: correlative study in a randomised clinical trial. Breast Cancer Res, 2014, 16(1): R8.
|
4. |
Johnson GA, Burghardt RC, Bazer FW. Osteopontin: a leading candidate adhesion molecule for implantation in pigs and sheep. J Anim Sci Biotechnol, 2014, 5(1): 56.
|
5. |
Wang KX, Denhardt DT. Osteopontin: role in immune regulation and stress response. Cytokine Growth Factor Rev, 2008, 19(5-6): 333-345.
|
6. |
Rittling SR, Singh R. Osteopontin in immune-mediated diseases. J Dent Res, 2015, 94(12): 1638-1645.
|
7. |
Cao DX, Li ZJ, Jiang XO, et al. Osteopontin as potential biomarker and therapeutic target in gastric and liver cancers. World J Gastroenterol, 2012, 18(30): 3923-3930.
|
8. |
Chae S, Jun HO, Lee EG, et al. Osteopontin splice variants differentially modulate the migratory activity of hepatocellular carcinoma cell lines. Int J Oncol, 2009, 35(6): 1409-1416.
|
9. |
Tang XJ, Li JF, Yu BQ, et al. Osteopontin splice variants differentially exert clinicopathological features and biological functions in gastric cancer. Int J Biol Sci, 2013, 9(1): 55-66.
|
10. |
Fong YC, Liu SC, Huang CY, et al. Osteopontin increases lung cancer cells migration via activation of the alphavbeta 3 integrin/FAK/Akt and NF-kappaB-dependent pathway. Lung Cancer, 2009, 64(3): 263-270.
|
11. |
Hiraga T, Ito S, Nakamura H. Cancer stem-like cell marker CD44 promotes bone metastases by enhancing tumorigenicity, cell motility, and hyaluronan production. Cancer Res, 2013, 73(13): 4112-4122.
|
12. |
Zhang H, Guo M, Chen JH, et al. Osteopontin knockdown inhibits av, β3 integrin-induced cell migration and invasion and promotes apoptosis of breast cancer cells by inducing autophagy and inactivating the PI3K/Akt/m TOR pathway. Cell Physiol Biochem, 2014, 33(4): 991-1002.
|
13. |
Hsu KH, Tsai HW, Lin PW, et al. Anti-apoptotic effects of osteopontin through the up-regulation of Mcl-1 in gastrointestinal stromal tumors. World J Surg Oncol, 2014, 12: 189.
|
14. |
Wu Y, Jiang W, Wang Y, et al. Breast cancer metastasis suppressor 1 regulates hepatocellular carcinoma cell apoptosis via suppressing osteopontin expression. PLoS One, 2012, 7(8): e42976.
|
15. |
Dai J, Peng L, Fan K, et al. Osteopontin induces angiogenesis through activation of PI3K/AKT and ERK1/2 in endothelial cells. Oncogene, 2009, 28(38): 3412-3422.
|
16. |
Chakraborty G, Jain S, Kundu GC. Osteopontin promotes vascular endothelial growth factor-dependent breast tumor growth and angiogenesis via autocrine and paracrine mechanisms. Cancer Res, 2008, 68(1): 152-161.
|
17. |
Wu XL, Lin KJ, Bai AP, et al. Osteopontin knockdown suppresses the growth and angiogenesis of colon cancer cells. World J Gastroenterol, 2014, 20(30): 10440-10448.
|
18. |
Wang Y, Yan W, Lu X, et al. Overexpression of osteopontin induces angiogenesis of endothelial progenitor cells via the avβ3/PI3K/AKT/eNOS/NO signaling pathway in glioma cells. Eur J Cell Biol, 2011, 90(8): 642-648.
|
19. |
Kale S, Raja R, Thorat D, et al. Osteopontin signaling upregulates cyclooxygenase-2 expression in tumor-associated macrophages leading to enhanced angiogenesis and melanoma growth via α9β1 integrin. Oncogene. 2015, 34(42): 5408-5410.
|
20. |
DeLisser HM. CD44: target for antiangiogenesis therapy. Blood, 2009, 114(25): 5114-5115.
|
21. |
Sherwood DR. Cell invasion through basement membranes: an anchor of understanding. Trends Cell Biol, 2006, 16(5): 250-256.
|
22. |
Song G, Ouyang G, Mao Y, et al. Osteopontin promotes gastric cancer metastasis by augmenting cell survival and invasion through Akt-mediated HIF-1alpha up-regulation and MMP9 activation. J Cell Mol Med, 2009, 13(8B): 1706-1718.
|
23. |
Sun BS, You J, Li Y, et al. Osteopontin knockdown suppresses non-small cell lung cancer cell invasion and metastasis. Chin Med J (Engl). 2013, 126(9): 1683-1688.
|
24. |
Gialeli C, Theocharis AD, Karamanos NK. Roles of matrix metalloproteinases in cancer progression and their pharmacological targeting. FEBS J, 2011, 278(1): 16-27.
|
25. |
Chen YJ, Wei YY, Chen HT, et al. Osteopontin increases migration and MMP-9 up-regulation via alphavbeta3 integrin, FAK, ERK, and NF-kappaB-dependent pathway in human chondrosarcoma cells. J Cell Physiol, 2009, 221(1): 98-108.
|
26. |
Behera R, Kumar V, Lohite K, et al. Activation of JAK2/STAT3 signaling by osteopontin promotes tumor growth in human breast cancer cells. Carcinogenesis, 2010, 31(2): 192-200.
|
27. |
Liu H, Chen AM, Guo FJ, et al. A short-hairpin RNA targeting osteopontin downregulates MMP-2 and MMP-9 expressions in prostate cancer PC-3 cells. Cancer Lett, 2010, 295(1): 27-37.
|
28. |
Zhang R, Pan X, Huang Z, et al. Osteopontin enhances the expression and activity of MMP-2 via the SDF-1/CXCR4 axis in hepatocellular carcinoma cell lines. PLoS One, 2011, 6(8): e23831.
|
29. |
Duffy MJ, McGowan PM, Harbeck N, et al. uPA and PAI-1 as biomarkers in breast cancer: validated for clinical use in level-of-evidence-1 studies. Breast Cancer Res, 2014, 16(4): 428.
|
30. |
Tang L, Han X. The urokinase plasminogen activator system in breast cancer invasion and metastasis. Biomed Pharmacother. 2013, 67(2): 179-182.
|
31. |
Mi ZY, Guo HT, Wai PY, et al. Integrin-linked kinase regulates osteopontin-dependent MMP-2 and uPA expression to convey metastatic function in murine mammary epithelial cancer cells. Carcinogenesis, 2006, 27(6): 1134-1145.
|
32. |
Das R, Mahabeleshwar GH, Kundu GC. Osteopontin stimulates cell motility and nuclear factor kappaB-mediated secretion of urokinase type plasminogen activator through phosphatidylinositol 3-kinase/Akt signaling pathways in breast cancer cells. J Biol Chem, 2003, 278(31): 28593-28606.
|
33. |
Chen RX, Xia YH, Xue TC, et al. Osteopontin promotes hepatocellular carcinoma invasion by up-regulating MMP-2 and uPA expression. Mol Biol Rep, 2011, 38(6): 3671-3677.
|
34. |
Lathia JD, Mack SC, Mulkearns-Hubert EE, et al. Cancer stem cells in glioblastoma. Genes Dev, 2015, 29(12): 1203-1217.
|
35. |
Lamour V, Henry A, Kroonen J, et al. Targeting osteopontin suppresses glioblastoma stem-like cell character and tumorigenicity in vivo. Int J Cancer, 2015, 137(5): 1047-1057.
|
36. |
Ng L, Wan T, Chow A, et al. Osteopontin overexpression induced tumor progression and chemoresistance to oxaliplatin through induction of stem-like properties in human colorectal cancer. Stem Cells Int, 2015, 2015: 247892.
|
37. |
Cao L, Fan X, Jing W, et al. Osteopontin promotes a cancer stem cell-like phenotype in hepatocellular carcinoma cells via an integrin-NF-κB-HIF-1α pathway. Oncotarget, 2015, 6(9): 6627-6640.
|
38. |
Li ZZ, Bao S, Wu QL, et al. Hypoxia-Inducible factors regulate tumorigenic capacity of glioma stem cells. Cancer Cell, 2009, 15(6): 501-513.
|
39. |
Semenza GL. Regulation of the breast cancer stem cell phenotype by hypoxia-inducible factors. Clin Sci, 2015, 129(12): 1037-1045.
|
40. |
Pietras A, Katz AM, Ekström EJ, et al. Osteopontin-CD44 signaling in the glioma perivascular niche enhances cancer stem cell phenotypes and promotes aggressive tumor growth. Cell Stem Cell, 2014, 14(3): 357-369.
|
41. |
Iqbal J, Mcrae S, Banaudha K, et al. Mechanism of hepatitis C virus (HCV)-induced osteopontin and its role in epithelial to mesenchymal transition of hepatocytes. J Biol Chem, 2013, 288(52): 36994-37009.
|
42. |
Takafuji V, Forgues M, Unsworth E, et al. An osteopontin fragment is essential for tumor cell invasion in hepatocellular carcinoma. Oncogene, 2007, 26(44): 6361-6371.
|
43. |
Tilli TM, Mello KD, Ferreira LB, et al. Both osteopontin-c and osteopontin-b splicing isoforms exert pro-tumorigenic roles in prostate cancer cells. Prostate, 2012, 72(15): 1688-1699.
|
44. |
Hartung F, Weber GF. RNA blood levels of osteopontin splice variants are cancer markers. Springerplus, 2013, 2(1): 110.
|
45. |
Zduniak K, Ziolkowski P, Ahlin C, et al. Nuclear osteopontin-c is a prognostic breast cancer marker. Br J Cancer, 2015, 112(4): 729-738.
|